<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00932152</url>
  </required_header>
  <id_info>
    <org_study_id>UPCI 08-131</org_study_id>
    <nct_id>NCT00932152</nct_id>
  </id_info>
  <brief_title>Fulvestrant and Anastrozole as Consolidation Therapy in Postmenopausal Women With Advanced Non-small Cell Lung Cancer</brief_title>
  <official_title>A Phase II Randomized Trial of Fulvestrant and Anastrozole as Consolidation Therapy in Postmenopausal Women With Advanced Non-small Cell Lung Cancer Who Have Received First-line Platinum-based Chemotherapy With or Without Bevacizumab</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research study will test whether dual anti-estrogen therapy (anastrozole and
      fulvestrant) slows the time to when the cancer progresses.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Women invited to participate in this study must be post-menopausal and be 18 years of age or
      older. The study is being performed on a total of 100 individuals. Of this group, 75 will be
      in the Treatment Groups using Fulvestrant/Anastrozole with our without bevacizumab and 25
      will be in the &quot;Best Supportive Care&quot; groups receiving no treatment or just bevacizumab at
      the University of Pittsburgh Medical Center.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Poor enrollment/suspended to accrual; will close per AstraZeneca request
  </why_stopped>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To Evaluate the Progression-free Survival.</measure>
    <time_frame>1.5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To Evaluate the Time to Overall Survival, Time to Progression, and Toxicities</measure>
    <time_frame>1.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Evaluate the Levels of 17b-estradiol, VEGF, E-selectin, Thrombospondin-1 and IGF-1, and Other Biomarkers in the Plasma.</measure>
    <time_frame>1.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Evaluate Biomarkers (ERa, ERb, PR, VEGF and Aromatase Expression) in Baseline, Archival Tumor Tissue and Correlate Their Expression With Progression-free Survival, Time to Progression, and Overall Survival.</measure>
    <time_frame>1.5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <condition>Postmenopausal Women</condition>
  <arm_group>
    <arm_group_label>Arm B, Group 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Best supportive care only: antibiotics, analgesics, antiemetics, thoracentesis, pleurodesis, blood transfusions, and/or nutritional support PRN</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B, Group 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Best supportive care and Bevacizumab 15mg/kg every 21 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm A, Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fulvestrant and anastrozole only</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm A, Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fulvestrant, anastrozole and Bevacizumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fulvestrant (Faslodex)</intervention_name>
    <description>Fulvestrant (Faslodex) IM 250 mg monthly after a loading dose of 500 mg on day 1 and 250 mg on day 15 of cycle 1.</description>
    <arm_group_label>Arm A, Group 1</arm_group_label>
    <arm_group_label>Arm A, Group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>anastrozole (Arimidex)</intervention_name>
    <description>Anastrozole (Arimidex) 1 mg orally QD</description>
    <arm_group_label>Arm A, Group 1</arm_group_label>
    <arm_group_label>Arm A, Group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab (Avastin)</intervention_name>
    <description>Bevacizumab (Avastin) 15 mg/kg IV, every 21 days</description>
    <arm_group_label>Arm B, Group 2</arm_group_label>
    <arm_group_label>Arm A, Group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Best supportive care</intervention_name>
    <description>Subjects will not receive any chemotherapy for NSCLC nor will they received anti-cancer surgery, immunotherapy, radiotherapy or hormonal therapy. Among the therapies they may take are therapies considered acceptable include, but are not limited to, antibiotics, analgesics, antiemetics, thoracentesis, pleurodesis, blood transfusions, and/or nutritional support (enteral or parenteral</description>
    <arm_group_label>Arm B, Group 1</arm_group_label>
    <arm_group_label>Arm B, Group 2</arm_group_label>
    <other_name>Antibiotics, analgesics, antiemetics, thoracentesis, pleurodesis, blood transfusions, and/or nutritional support</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologic or cytologic diagnosis of non-small cell lung cancer (NSCLC) (no component
             of small cell).

          -  Patients must have stage IIIB (with malignant pleural effusion), stage IV NSCLC (as
             staged by the AJCC Cancer Staging Manual. 6th ed, appendix 1) or stage IV NSCLC as
             staged by the new AJCC staging system

          -  Patients with recurrent NSCLC should have recurred 12 months or more after completion
             of prior chemotherapy given in the context of curative therapy (chemoradiotherapy or
             adjuvant therapy) are eligible

          -  Patients should have been treated with 4 cycles of induction chemotherapy utilizing
             the following regimens: carboplatin/paclitaxel, carboplatin/gemcitabine,
             carboplatin/paclitaxel + bevacizumab, carboplatin/gemcitabine + bevacizumab, or
             carboplatin/pemetrexed +/- bevacizumab, (see Section 3.2 for acceptable doses and
             schedules) and should have CR, PR, or SD as best response.

          -  Patients should not have progressed on prior chemotherapy for metastatic or recurrent
             NSCLC.

          -  Must be postmenopausal female, as defined by the following criteria:

               -  Prior bilateral oophorectomy or

               -  Age greater than 60 years old

               -  Age less than 60 years old and amenorrheic for 12 or more months in the absence
                  of chemotherapy or ovarian suppression with FSH and estradiol in the
                  postmenopausal range.

          -  Registration/randomization should be within 6 weeks of beginning of last cycle of
             chemotherapy

          -  Documented evidence of a tumor response of CR, PR, or SD. Tumor assessment must occur
             between Cycle 4 (Day 1) of induction therapy and the date of randomization. Tumor
             assessment will be per RECIST (Appendix 3) by the treating physician. This response
             does not have to be confirmed in order for the patient to be randomized; however,
             unconfirmed responses will be stratified in the stable disease strata. Positron
             emission tomography (PET) scans and ultrasound may not be used for lesion measurements
             for response determination

          -  ECOG performance status 0, 1 or 2.

          -  At least 18 years of age.

          -  Adequate organ function, including the following:

        Adequate bone marrow reserve: absolute neutrophil (segmented and bands) count (ANC) greater
        than or equal to 1.0 x10^9/L, platelets greater than or equal to 75 x10^9/L, and hemoglobin
        greater than or equal to 9 g/dL.

        Hepatic: bilirubin less than or equal to 1.5 times the upper limit of normal (ULN),
        alkaline phosphatase (ALP), aspartate transaminase (AST), and alanine transaminase (ALT)
        less than or equal to 2.0 Renal: calculated creatinine clearance (CrCl) â‰¥45 mL/min based on
        the standard Cockcroft and Gault formula (Cockcroft and Gault 1976).

          -  Prior radiotherapy must be completed at least 3 weeks before study enrollment.
             Patients must have recovered from the acute toxic effects of the treatment prior to
             study enrollment.

          -  Signed informed consent document on file.

          -  Patient compliance and geographic proximity that allow adequate follow up.

          -  Patient must receive on-study therapy no earlier than 21 days and no later than 42
             days from their last cycle (Day 1) of induction therapy.

          -  Patients must have archival tissue samples. Tumor tissue will be submitted for
             assessment of ERa, ERb, PR, VEGF and aromatase expression. The patient must also agree
             to mandatory correlative blood samples at baseline, 5 weeks, 9 weeks, 13 weeks and at
             the time of progression.

          -  Cisplatin may be used instead of carboplatin as part of the initial induction
             chemotherapy regimen, at the discretion of the treating physician investigator. The
             dose and schedule of cisplatin will be according to the standard of care for patients
             with stage IIIB with malignant pleural effusion or stage IV NSCLC as staged by the
             AJCC Cancer Staging Manual, 6th ed, appendix 1, that is equivalent to stage IV NSCLC
             as staged by the new 7th ed AJCC staging system.

        Exclusion Criteria:

          -  Male gender

          -  With the exception of those chemotherapies listed as Inclusion criterion (4) No other
             concomitant biological therapy (e.g. cetuximab) is allowed.

          -  Have received experimental treatment within the last 30 days at the time of study
             entry.

          -  Inability to comply with protocol or study procedures.

          -  A serious concomitant systemic disorder that, in the opinion of the investigator,
             would compromise the patient's ability to complete the study.

          -  Concurrent administration of any other antitumor therapy (except arm B, who are
             allowed to continue with bevacizumab).

          -  Pregnant or breast feeding.

          -  Have a prior malignancy other than NSCLC, carcinoma in situ of the cervix, or
             nonmelanoma skin cancer, unless that prior malignancy was diagnosed and definitively
             treated at least 5 years previously with no subsequent evidence of recurrence.

          -  Patients with two or more deep vein thromboses, or an active deep vein thrombosis.

          -  Patients taking hormone replacement therapy or other hormonal therapies

          -  The International Normalized Ratio (INR) must be &lt; 1.6 within 28 days prior to
             registration.

          -  Patients with bleeding diathesis (i.e., disseminated intravascular coagulation [DIC],
             clotting factor deficiency) or a history of recent history of hemoptysis (1/2 tsp of
             red blood). Patients on stable long term anticoagulation prior to starting this trial
             are allowed.

          -  History of hypersensitivity to active or inactive excipients of fulvestrant (ie castor
             oil or Mannitol).

          -  Treatment of NSCLC with squamous cell histology with bevacizumab.

          -  No progressive Brain or CNS metastases

          -  No other concurrent anticancer therapy is allowed other than Bevacizumab
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ahmad Tarhini, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Pittsburgh Cancer Institute</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 1, 2009</study_first_submitted>
  <study_first_submitted_qc>July 2, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 3, 2009</study_first_posted>
  <results_first_submitted>January 14, 2016</results_first_submitted>
  <results_first_submitted_qc>July 19, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 31, 2016</results_first_posted>
  <last_update_submitted>September 18, 2017</last_update_submitted>
  <last_update_submitted_qc>September 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Ahmad Tarhini</investigator_full_name>
    <investigator_title>Associate Professor of Medicine and Translational Science</investigator_title>
  </responsible_party>
  <keyword>advanced non-small cell lung cancer</keyword>
  <keyword>postmenopausal</keyword>
  <keyword>bevacizumab</keyword>
  <keyword>fulvestrant</keyword>
  <keyword>anastrozole</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Fulvestrant</mesh_term>
    <mesh_term>Anastrozole</mesh_term>
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
    <mesh_term>Analgesics</mesh_term>
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Antiemetics</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>No participants were randomized to the &quot;Best supportive care only&quot; and &quot;Best supportive care with Bevacizumab&quot; Arms due to low recruitment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Fulvestrant and Anastrozole Only</title>
        </group>
        <group group_id="P2">
          <title>Fulvestrant, Anastrozole and Bevacizumab</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Fulvestrant and Anastrozole Only</title>
        </group>
        <group group_id="B2">
          <title>Fulvestrant, Anastrozole and Bevacizumab</title>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
            <count group_id="B2" value="2"/>
            <count group_id="B3" value="3"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67" lower_limit="67" upper_limit="67"/>
                    <measurement group_id="B2" value="67.5" lower_limit="58" upper_limit="77"/>
                    <measurement group_id="B3" value="67" lower_limit="58" upper_limit="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>To Evaluate the Progression-free Survival.</title>
        <time_frame>1.5 years</time_frame>
        <population>Analysis was not completed because the trial was stopped prematurely due to slow accrual.</population>
        <group_list>
          <group group_id="O1">
            <title>All Participants (Overall Study)</title>
          </group>
        </group_list>
        <measure>
          <title>To Evaluate the Progression-free Survival.</title>
          <population>Analysis was not completed because the trial was stopped prematurely due to slow accrual.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Evaluate the Time to Overall Survival, Time to Progression, and Toxicities</title>
        <time_frame>1.5 years</time_frame>
        <population>No data displayed because Outcome Measure has zero total participants analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Fulvestrant and Anastrozole Only</title>
          </group>
          <group group_id="O2">
            <title>Fulvestrant, Anastrozole and Bevacizumab</title>
          </group>
        </group_list>
        <measure>
          <title>To Evaluate the Time to Overall Survival, Time to Progression, and Toxicities</title>
          <population>No data displayed because Outcome Measure has zero total participants analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Evaluate the Levels of 17b-estradiol, VEGF, E-selectin, Thrombospondin-1 and IGF-1, and Other Biomarkers in the Plasma.</title>
        <time_frame>1.5 years</time_frame>
        <population>No data displayed because Outcome Measure has zero total participants analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Fulvestrant and Anastrozole Only</title>
          </group>
          <group group_id="O2">
            <title>Fulvestrant, Anastrozole and Bevacizumab</title>
          </group>
        </group_list>
        <measure>
          <title>To Evaluate the Levels of 17b-estradiol, VEGF, E-selectin, Thrombospondin-1 and IGF-1, and Other Biomarkers in the Plasma.</title>
          <population>No data displayed because Outcome Measure has zero total participants analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Evaluate Biomarkers (ERa, ERb, PR, VEGF and Aromatase Expression) in Baseline, Archival Tumor Tissue and Correlate Their Expression With Progression-free Survival, Time to Progression, and Overall Survival.</title>
        <time_frame>1.5 years</time_frame>
        <population>No data displayed because Outcome Measure has zero total participants analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Fulvestrant and Anastrozole Only</title>
          </group>
          <group group_id="O2">
            <title>Fulvestrant, Anastrozole and Bevacizumab</title>
          </group>
        </group_list>
        <measure>
          <title>To Evaluate Biomarkers (ERa, ERb, PR, VEGF and Aromatase Expression) in Baseline, Archival Tumor Tissue and Correlate Their Expression With Progression-free Survival, Time to Progression, and Overall Survival.</title>
          <population>No data displayed because Outcome Measure has zero total participants analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Adverse events were not collected/monitored &quot;per Arm/Group&quot;</desc>
      <group_list>
        <group group_id="E1">
          <title>All Participants (Overall Study)</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Obstruction, GI, Small bowel NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Calcium, serum-high (hypercalcemia)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neurology - Other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Thyroid function, low (hypothyroidism)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Watery eye (epiphora, tearing)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Mucositis/stomatitis (functional/symptomatic), Oral cavity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Pain, Abdomen NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue (asthenia, lethargy, malaise)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Rigors/chills</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils, Conjunctiva</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Leukocytes (total WBC)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Neutrophils/granulocytes (ANC/AGC)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>ALT, SGPT (serum glutamic pyruvic transaminase)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>AST, SGOT(serum glutamic oxaloacetic transaminase)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Bilirubin (hyperbilirubinemia)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Bicarbonate, serum-low</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Glucose, serum-high (hyperglycemia)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Glucose, serum-low (hypoglycemia)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain, Back</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Pain, Extremity-limb</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neurology - Other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Neuropathy: sensory</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Pain, Head/headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mood alteration, Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Glomerular filtration rate</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Vaginal dryness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Dyspnea (shortness of breath)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatology/Skin - Other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Hair loss/alopecia (scalp or body)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Rash: acne/acneiform</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Hot flashes/flushes</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Ahmad Tarhini, MD</name_or_title>
      <organization>University of Pittsburgh</organization>
      <phone>(412) 648-6578</phone>
      <email>tarhiniaa@upmc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

